Aspen Pharmacare resolves its mRNA dispute with a R500m settlement, stabilising its earnings and share price significantly.
Aspen Pharmacare Dispute Ends with R500m Settlement
Original Article by Jacob Webster | Business Day | 3 November 2025
Aspen Pharmacare resolves its mRNA dispute with a R500m settlement, stabilising its earnings and share price significantly.
More Posts
Acute Pain in African Hospitals Affects Two-Thirds of Patients
Acute pain in African hospitals affects two-thirds of patients – what the burden means for hospital groups and medical schemes.
Read more...
Mpox Cases in SA Rise as Local Transmission Accelerates
Mpox cases in South Africa are rising, mainly in the Western Cape. What the surge means for the healthcare industry.
Read more...
NHLS Scrambles as Pathology Services Funding Runs Dry
The NHLS is scrambling for new providers after funds for haematology pathology services ran dry, amid an R11.3bn provincial debt
Read more...